Goldman Sachs Removes Hologic (HOLX) from Conviction Buy List
Tweet
Share
E-mailGet Alerts HOLX Hot Sheet
Price: $76.01 --0%
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs removed its Conviction Buy List rating on Hologic (NASDAQ: HOLX) but is keeping its Buy rating and $22 6-month price target, which suggests 33% upside.
The firm remains positive on tomosynthesis, but says broader concerns around healthcare utilization could outweigh our product cycle thesis for the near term.
For more ratings news on Hologic click here and for the rating history of Hologic click here.
Shares of Hologic closed at $16.53 yesterday.
The firm remains positive on tomosynthesis, but says broader concerns around healthcare utilization could outweigh our product cycle thesis for the near term.
For more ratings news on Hologic click here and for the rating history of Hologic click here.
Shares of Hologic closed at $16.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- DA Davidson Downgrades Blaize Inc. (BZAI) to Neutral
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
